Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020880108> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2020880108 endingPage "752" @default.
- W2020880108 startingPage "745" @default.
- W2020880108 abstract "For individuals with emphysema because of severe alpha(1)-antitrypsin deficiency, specific therapy called IV augmentation therapy has been available since 1989. Such therapy consists of IV infusion of pooled human plasma alpha(1)-antiprotease.To assess the direct medical costs of having alpha(1)-antitrypsin deficiency, the current study surveyed members of the Alpha One Foundation Registry for Individuals With alpha(1)-Antitrypsin Deficiency regarding their annual expenditures for treatment of this disease. Data regarding demographic features, alpha(1)-antitrypsin status, and health-resource utilization were collected from a self-administered questionnaire. Respondents were asked to provide total health-care expenditures, but costs by specific items of care (eg, drugs, physician visits, etc) were not available.Mean annual cost estimates were higher for PI*ZZ-phenotype individuals ($30,948, n = 292) than for non-PI*ZZ-phenotype individuals ($20,673, n = 53; p = 0.049). Among PI*ZZ-phenotype individuals, self-reported costs of health-care services were further analyzed for those 288 individuals whose alpha(1)-antiprotease use status was reported. For the 185 current alpha(1)-antiprotease users, the mean annual cost was $40,123 (median, $36,000).Annual health-care expenditures by individuals with alpha(1)-antitrypsin deficiency are very high, whether or not they are currently receiving augmentation therapy. Augmentation therapy adds substantial costs, especially for heavier individuals who are receiving weekly infusions." @default.
- W2020880108 created "2016-06-24" @default.
- W2020880108 creator A5008007589 @default.
- W2020880108 creator A5027695585 @default.
- W2020880108 creator A5045850263 @default.
- W2020880108 creator A5073266750 @default.
- W2020880108 date "2001-03-01" @default.
- W2020880108 modified "2023-09-25" @default.
- W2020880108 title "The Direct Medical Costs of α1-Antitrypsin Deficiency" @default.
- W2020880108 cites W1978575482 @default.
- W2020880108 cites W1982468029 @default.
- W2020880108 cites W1993347912 @default.
- W2020880108 cites W1993963246 @default.
- W2020880108 cites W2059220887 @default.
- W2020880108 cites W2073861177 @default.
- W2020880108 cites W2086542767 @default.
- W2020880108 cites W2087120421 @default.
- W2020880108 cites W2098777305 @default.
- W2020880108 cites W2113041802 @default.
- W2020880108 cites W2334275983 @default.
- W2020880108 doi "https://doi.org/10.1378/chest.119.3.745" @default.
- W2020880108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11243952" @default.
- W2020880108 hasPublicationYear "2001" @default.
- W2020880108 type Work @default.
- W2020880108 sameAs 2020880108 @default.
- W2020880108 citedByCount "41" @default.
- W2020880108 countsByYear W20208801082012 @default.
- W2020880108 countsByYear W20208801082014 @default.
- W2020880108 countsByYear W20208801082015 @default.
- W2020880108 countsByYear W20208801082017 @default.
- W2020880108 countsByYear W20208801082018 @default.
- W2020880108 countsByYear W20208801082019 @default.
- W2020880108 countsByYear W20208801082020 @default.
- W2020880108 countsByYear W20208801082021 @default.
- W2020880108 countsByYear W20208801082022 @default.
- W2020880108 crossrefType "journal-article" @default.
- W2020880108 hasAuthorship W2020880108A5008007589 @default.
- W2020880108 hasAuthorship W2020880108A5027695585 @default.
- W2020880108 hasAuthorship W2020880108A5045850263 @default.
- W2020880108 hasAuthorship W2020880108A5073266750 @default.
- W2020880108 hasConcept C126322002 @default.
- W2020880108 hasConcept C141071460 @default.
- W2020880108 hasConcept C160735492 @default.
- W2020880108 hasConcept C162324750 @default.
- W2020880108 hasConcept C2775944032 @default.
- W2020880108 hasConcept C2779134260 @default.
- W2020880108 hasConcept C2780535462 @default.
- W2020880108 hasConcept C49453240 @default.
- W2020880108 hasConcept C50522688 @default.
- W2020880108 hasConcept C64943373 @default.
- W2020880108 hasConcept C71924100 @default.
- W2020880108 hasConcept C74909509 @default.
- W2020880108 hasConceptScore W2020880108C126322002 @default.
- W2020880108 hasConceptScore W2020880108C141071460 @default.
- W2020880108 hasConceptScore W2020880108C160735492 @default.
- W2020880108 hasConceptScore W2020880108C162324750 @default.
- W2020880108 hasConceptScore W2020880108C2775944032 @default.
- W2020880108 hasConceptScore W2020880108C2779134260 @default.
- W2020880108 hasConceptScore W2020880108C2780535462 @default.
- W2020880108 hasConceptScore W2020880108C49453240 @default.
- W2020880108 hasConceptScore W2020880108C50522688 @default.
- W2020880108 hasConceptScore W2020880108C64943373 @default.
- W2020880108 hasConceptScore W2020880108C71924100 @default.
- W2020880108 hasConceptScore W2020880108C74909509 @default.
- W2020880108 hasIssue "3" @default.
- W2020880108 hasLocation W20208801081 @default.
- W2020880108 hasLocation W20208801082 @default.
- W2020880108 hasOpenAccess W2020880108 @default.
- W2020880108 hasPrimaryLocation W20208801081 @default.
- W2020880108 hasRelatedWork W2400210712 @default.
- W2020880108 hasRelatedWork W2401005838 @default.
- W2020880108 hasRelatedWork W2402024466 @default.
- W2020880108 hasRelatedWork W2405952595 @default.
- W2020880108 hasRelatedWork W2426579790 @default.
- W2020880108 hasRelatedWork W2894818418 @default.
- W2020880108 hasRelatedWork W2908382401 @default.
- W2020880108 hasRelatedWork W4251103160 @default.
- W2020880108 hasRelatedWork W4290385523 @default.
- W2020880108 hasRelatedWork W2254986585 @default.
- W2020880108 hasVolume "119" @default.
- W2020880108 isParatext "false" @default.
- W2020880108 isRetracted "false" @default.
- W2020880108 magId "2020880108" @default.
- W2020880108 workType "article" @default.